Menu
Back to User profile » Dr Shane Kannarr
Papers published by Dr Shane Kannarr:
A Randomized, Controlled Trial Comparing Tearcare® and Cyclosporine Ophthalmic Emulsion for the Treatment of Dry Eye Disease (SAHARA) [Response To Letter]
Ayres BD, Bloomenstein MR, Loh J, Chester T, Saenz B, Ehegoyen J, Kannarr SR, Perez VL, Rodriguez TC, Dickerson JE Jr
Clinical Ophthalmology 2024, 18:885-886
Published Date: 20 March 2024
A Randomized, Controlled Trial Comparing Tearcare® and Cyclosporine Ophthalmic Emulsion for the Treatment of Dry Eye Disease (SAHARA)
Ayres BD, Bloomenstein MR, Loh J, Chester T, Saenz B, Echegoyen J, Kannarr SR, Perez VL, Rodriguez TC, Dickerson Jr JE
Clinical Ophthalmology 2023, 17:3925-3940
Published Date: 18 December 2023
Real-World Use of Loteprednol Etabonate 0.5%/Tobramycin 0.3% Ophthalmic Suspension for the Treatment of Ocular Surface Inflammatory Conditions
Deom JE, Kannarr S, Vollmer P
Clinical Ophthalmology 2022, 16:3803-3809
Published Date: 17 November 2022
Systane iLux Thermal Pulsation System in the Treatment of Meibomian Gland Dysfunction: A Post-Hoc Analysis of a 12-Month, Randomized, Multicenter Study
Wesley G, Bickle K, Downing J, Fisher B, Greene B, Heinrich C, Kading D, Kannarr S, Miller J, Modi S, Ludwick D, Tauber J, Yeh TN, Srinivasan S
Clinical Ophthalmology 2022, 16:3631-3640
Published Date: 3 November 2022
Safety of Once-Daily Oxymetazoline HCl Ophthalmic Solution, 0.1% in Patients with Acquired Blepharoptosis: Results from Four Randomized, Double-Masked Clinical Trials
Wirta DL, Korenfeld MS, Foster S, Smyth-Medina R, Bacharach J, Kannarr SR, Jaros MJ, Slonim CB
Clinical Ophthalmology 2021, 15:4035-4048
Published Date: 8 October 2021
Rapid and Sustained Eyelid Elevation in Acquired Blepharoptosis with Oxymetazoline 0.1%: Randomized Phase 3 Trial Results
Bacharach J, Wirta DL, Smyth-Medina R, Korenfeld MS, Kannarr SR, Foster S, Jaros MJ, Slonim CB
Clinical Ophthalmology 2021, 15:2743-2751
Published Date: 25 June 2021
A Review of Topical Cyclosporine A Formulations—A Disease-Modifying Agent for Keratoconjunctivitis Sicca
Jerkins GW, Pattar GR, Kannarr SR
Clinical Ophthalmology 2020, 14:481-489
Published Date: 20 February 2020